MKS Enterprise, LLC - 624478 - 07/01/2022

Why It Matters

Undeclared pharmaceuticals in dietary supplements pose serious health risks and expose companies to significant legal liability, prompting tighter regulatory scrutiny across the supplement market.

Key Takeaways

• FDA found undeclared tadalafil in Vital Honey
• Product marketed as food but makes drug claims
• Violates FD&C Act sections 301(ll) and 502(f)(1)
• Misbranding due to lack of usage directions
• Company must respond within 15 working days

Pulse Analysis

The discovery of tadalafil—a prescription erectile‑dysfunction drug—in a honey‑based supplement underscores a growing trend of adulterated nutraceuticals. Consumers seeking natural remedies are increasingly exposed to hidden pharmaceuticals that can interact dangerously with existing medications, especially cardiovascular drugs. FDA’s laboratory testing of Vital Honey illustrates how routine surveillance can uncover such violations, reinforcing the agency’s commitment to protecting public health amid a booming online supplement market.

Under the Federal Food, Drug, and Cosmetic Act, adding a regulated drug to a food product without approval constitutes a prohibited act under section 301(ll). The agency also deemed Vital Honey a "new drug" because the company’s website touted unsubstantiated health benefits, ranging from arthritis prevention to cholesterol reduction. These claims trigger misbranding provisions, as the product lacks adequate directions for safe self‑administration. For e‑commerce sellers, the case highlights the legal peril of blending dietary‑supplement marketing with therapeutic language without FDA clearance.

The broader industry impact is clear: manufacturers must implement rigorous ingredient verification and label compliance programs. Failure to do so can result in costly warning letters, product seizures, and lasting damage to brand reputation. As regulators intensify scrutiny of online supplement sales, companies that proactively audit their supply chains and adhere to FDA guidance will better safeguard consumers and maintain market credibility. Continued vigilance will likely drive stricter enforcement actions, prompting a shift toward greater transparency and scientific substantiation in product claims.